Compare RTX & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTX | TMO |
|---|---|---|
| Founded | 1934 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Industrial Machinery/Components |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.3B | 216.4B |
| IPO Year | N/A | N/A |
| Metric | RTX | TMO |
|---|---|---|
| Price | $181.80 | $574.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 20 |
| Target Price | $177.57 | ★ $630.42 |
| AVG Volume (30 Days) | ★ 4.6M | 1.6M |
| Earning Date | 01-27-2026 | 01-29-2026 |
| Dividend Yield | ★ 1.52% | 0.30% |
| EPS Growth | ★ 38.64 | 8.54 |
| EPS | 4.87 | ★ 17.32 |
| Revenue | ★ $85,988,000,000.00 | $43,736,000,000.00 |
| Revenue This Year | $8.82 | $4.33 |
| Revenue Next Year | $6.17 | $4.94 |
| P/E Ratio | $36.69 | ★ $33.05 |
| Revenue Growth | ★ 8.79 | 3.22 |
| 52 Week Low | $112.27 | $385.46 |
| 52 Week High | $181.31 | $610.97 |
| Indicator | RTX | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 67.28 | 51.39 |
| Support Level | $170.35 | $561.91 |
| Resistance Level | $172.09 | $579.08 |
| Average True Range (ATR) | 3.45 | 11.08 |
| MACD | 0.93 | -2.43 |
| Stochastic Oscillator | 99.48 | 34.19 |
RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).